Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Increased plasma valproate concentrations when coadministered with guanfacine

P J Ambrosini1, R M Sheikh

  • 1Division of Child and Adolescent Psychiatry, Allegheny University of the Health Sciences, Eastern Pennsylvania Psychiatric Institute, Philadelphia 19129, USA.

Journal of Child and Adolescent Psychopharmacology
|September 8, 1998
PubMed
Summary

Guanfacine may increase valproate levels in children. This drug interaction, observed in two pediatric patients, suggests careful monitoring of valproate concentrations when coadministering these medications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

49th Annual Meeting of the American Academy of Child & Adolescent Psychiatry. 22-27 October 2002, San Francisco, CA, USA.

Expert opinion on pharmacotherapy·2003
Same author

Olanzapine versus haloperidol in children with autistic disorder: an open pilot study.

Journal of the American Academy of Child and Adolescent Psychiatry·2001
Same author

Childhood depression: pharmacological therapy/treatment (pharmacotherapy of childhood depression).

Journal of clinical child psychology·2001
Same author

A review of pharmacotherapy of major depression in children and adolescents.

Psychiatric services (Washington, D.C.)·2000
Same author

Historical development and present status of the schedule for affective disorders and schizophrenia for school-age children (K-SADS).

Journal of the American Academy of Child and Adolescent Psychiatry·2000
Same author

Multicenter open-label sertraline study in adolescent outpatients with major depression.

Journal of the American Academy of Child and Adolescent Psychiatry·1999

Area of Science:

  • Pharmacology
  • Clinical Pharmacy
  • Pediatric Medicine

Background:

  • Valproic acid is a widely used antiepileptic and mood-stabilizing drug.
  • Guanfacine is an alpha-2 adrenergic agonist used for ADHD and hypertension.
  • Concurrent use of these medications in pediatric patients necessitates understanding potential drug interactions.

Observation:

  • Two pediatric patients (8 and 9 years old) received concurrent valproic acid and guanfacine therapy.
  • In one patient, discontinuing guanfacine led to a 41% decrease in plasma valproate concentration.
  • In another patient, guanfacine administration was associated with a rapid increase in plasma valproate levels.

Findings:

  • Concurrent administration of guanfacine with valproic acid may significantly alter valproate plasma levels.

Related Experiment Videos

  • Observed changes suggest a potential pharmacokinetic interaction between guanfacine and valproic acid.
  • The interaction may involve competition for hepatic glucuronidation pathways or alterations in protein binding.

    • Implications:

    • Clinicians should exercise caution when prescribing guanfacine with valproic acid in pediatric populations.
    • Monitoring of valproate plasma concentrations is recommended during coadministration to prevent toxicity or subtherapeutic levels.
    • Further research is warranted to elucidate the precise mechanism and clinical significance of this drug interaction.